Last 32 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.26 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.41 | 0.70 | 2.09 | 1.42 | 0.66 | 0.41 | 0.24 | 0.33 | 0.51 | 0.52 | 0.63 | 0.28 | 0.28 | 0.36 | 0.27 | 0.23 | 0.42 | 0.66 | 0.63 | 0.71 | 0.75 |
| — | +68.8% | +770.2% | +331.7% | +30.8% | -20.4% | -61.7% | +18.6% | +78.5% | +43.9% | +135.7% | +19.0% | -32.4% | -45.0% | -57.7% | -67.1% | -43.9% | -21.8% | -36.4% | -30.5% | -4.9% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -111.2% | -76.6% | -31.8% | -32.2% | -31.2% | -61.3% | -18.1% | -16.5% | -14.3% | -16.7% | -16.0% | -12.0% | -10.8% | -12.2% | -10.0% | -9.9% | -10.0% | -8.7% | -9.2% | -7.0% | -7.0% |
| — | -25.1% | -75.6% | -95.8% | -117.6% | -266.9% | -12.9% | -37.0% | -32.7% | -36.8% | -60.2% | -21.2% | -8.4% | -40.4% | -8.6% | -40.9% | -42.2% | -31.2% | -59.6% | -36.7% | -34.7% | |
| ROA | -85.2% | -49.2% | -22.2% | -21.0% | -19.8% | -46.7% | -14.8% | -13.6% | -12.0% | -14.1% | -14.1% | -10.8% | -9.8% | -11.1% | -9.1% | -9.2% | -9.5% | -8.4% | -8.9% | -6.8% | -6.7% |
| — | -5.3% | -49.8% | -55.1% | -65.2% | -230.0% | -5.4% | -25.5% | -22.7% | -27.2% | -53.8% | -16.7% | -2.2% | -33.2% | -3.3% | -36.6% | -41.9% | -31.5% | -60.1% | -36.4% | -33.5% | |
| ROIC | -149.5% | -128.3% | -49.6% | -41.6% | -25.3% | -56.9% | -20.9% | -19.2% | -15.1% | -15.7% | -14.1% | -10.7% | -9.9% | -11.3% | -9.2% | -8.9% | -9.0% | -7.3% | -7.3% | -5.9% | -6.3% |
| — | -125.4% | -137.5% | -116.6% | -67.5% | -263.6% | -48.4% | -79.2% | -51.7% | -38.0% | -53.0% | -20.0% | -10.4% | -55.7% | -25.1% | -50.9% | -43.6% | -29.0% | -44.9% | -34.4% | -41.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.15 | 0.35 | 0.18 | 0.15 | 0.20 | 0.17 | 0.10 | 0.09 | 0.08 | 0.07 | 0.07 | 0.06 | 0.05 | 0.05 | 0.04 | 0.04 | — | — | — | — | — |
| — | +110.5% | +76.3% | +62.3% | +167.4% | +132.6% | +56.4% | +57.4% | +55.0% | +58.7% | +59.9% | +35.8% | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.14 | 3.47 | 4.61 | 4.14 | 2.97 | 3.71 | 10.26 | 7.50 | 9.07 | 8.35 | 10.70 | 16.38 | 18.72 | 17.30 | 23.77 | 17.97 | 29.76 | 33.87 | 32.52 | 34.48 | 32.95 |
| — | -6.5% | -55.1% | -44.8% | -67.3% | -55.5% | -4.1% | -54.2% | -51.5% | -51.7% | -55.0% | -8.8% | -37.1% | -48.9% | -26.9% | -47.9% | -9.7% | +12.2% | -2.5% | +23.6% | -36.3% | |
| Quick Ratio | 4.14 | 3.47 | 4.61 | 4.14 | 2.97 | 3.71 | 10.26 | 7.50 | 9.07 | 8.35 | 10.70 | 16.38 | 18.72 | 17.30 | 23.77 | 17.97 | 29.76 | 33.87 | 32.52 | 34.48 | 32.95 |
| — | -6.5% | -55.1% | -44.8% | -67.3% | -55.5% | -4.1% | -54.2% | -51.5% | -51.7% | -55.0% | -8.8% | -37.1% | -48.9% | -26.9% | -47.9% | -9.7% | +12.2% | -2.5% | +23.6% | -36.3% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 32 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NXTC stock.
NextCure, Inc.'s current P/E is -0.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking NextCure, Inc.'s business trajectory between earnings reports.